Transgene SA (FR:TNG)
PARIS:TNG
Holding FR:TNG?
Track your performance easily

Transgene (TNG) Stock Price & Analysis

3 Followers

TNG Stock Chart & Stats


TNG FAQ

What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.83 and its highest was €1.52 in the past 12 months.
    What is Transgene SA’s market cap?
    Currently, no data Available
    When is Transgene SA’s upcoming earnings report date?
    Transgene SA’s upcoming earnings report date is Mar 12, 2025 which is in 117 days.
      How were Transgene SA’s earnings last quarter?
      Currently, no data Available
      Is Transgene SA overvalued?
      According to Wall Street analysts Transgene SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Transgene SA pay dividends?
        Transgene SA does not currently pay dividends.
        What is Transgene SA’s EPS estimate?
        Transgene SA’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Transgene SA have?
        Transgene SA has 132,293,930 shares outstanding.
          What happened to Transgene SA’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Transgene SA?
          Currently, no hedge funds are holding shares in FR:TNG
          ---

          Transgene Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -44.03%
          12-Months-Change

          Fundamentals

          Return on Equity
          -214.69%
          Trailing 12-Months
          Asset Growth
          2.43%
          Trailing 12-Months

          Company Description

          Transgene SA

          Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Transgene
          4basebio UK Societas
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis